TY - JOUR
T1 - High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer
AU - Braunschweig, I.
AU - Mirza, N. Q.
AU - Rondon, G.
AU - Lauppe, J.
AU - Mehra, R.
AU - Gajewski, J.
AU - Körbling, M.
AU - Huh, Y. O.
AU - Geisler, D.
AU - Gee, A. P.
AU - Champlin, R.
AU - Przepiorka, D.
N1 - Funding Information:
Supported in part by The Tony Anderson Fund, and grants CA-16672 and T32 CA-09666 from the National Institutes of Health.
PY - 2000
Y1 - 2000
N2 - Background: Some transplant-related complications, such as the engraftment syndrome, are thought to be mediated by cytokines released during expansion of hematopoietic progenitors at the time of neutrophil recovery. Since there is an inverse correlation between CD34+ cell dose and time to neutrophil recovery, we sought to determine if peritransplant toxicity and early mortality were adversely affected by high CD34+ cell doses. Methods: The study group included 186 women with breast cancer who received high-dose cyclophosphamide, carmustine, thiotepa and an autologous PBSC transplant. The median CD34+ cell dose was 5.9 X 106/kg (1.0-154.7 X 106/kg). Patients were categorized by CD34+ cell dose (1.0-3.5, 3.6-5.9, 6.0-19.9, and 20.0-154.7 X 106/kg) for assessment of outcomes. Results: Grades 2-4 mucositis occurred in 49%, cardiac toxicity in 7%, pulmonary toxicity in 5%, cystitis in 4%, diarrhea in 3%, renal toxicity in 1%, and central nervous system toxicity in 1%. A Grade 2-4 regimen-related toxicity occurred in 109 patients (59%) and Grade 3-4 in eight patients (4%). Overall survival was 100% at Day 30, 96% at Day 90, and 89% at 1 year. Treatment-related mortality was 3.8%. In multivariate analyses that included prior chemotherapy, disease status, visceral metastases, prior chest radiation and age, CD34+ cell dose group was not an independent risk factor for Grade 2-4 mucositis, Grade 2-4 maximum toxicity, Grade ≥3 cumulative toxicity, 90 day survival or 1 year survival. Discussion: We conclude that CD34+ cell doses >20 X 106/kg do not affect transplant outcome in a negative or positive fashion.
AB - Background: Some transplant-related complications, such as the engraftment syndrome, are thought to be mediated by cytokines released during expansion of hematopoietic progenitors at the time of neutrophil recovery. Since there is an inverse correlation between CD34+ cell dose and time to neutrophil recovery, we sought to determine if peritransplant toxicity and early mortality were adversely affected by high CD34+ cell doses. Methods: The study group included 186 women with breast cancer who received high-dose cyclophosphamide, carmustine, thiotepa and an autologous PBSC transplant. The median CD34+ cell dose was 5.9 X 106/kg (1.0-154.7 X 106/kg). Patients were categorized by CD34+ cell dose (1.0-3.5, 3.6-5.9, 6.0-19.9, and 20.0-154.7 X 106/kg) for assessment of outcomes. Results: Grades 2-4 mucositis occurred in 49%, cardiac toxicity in 7%, pulmonary toxicity in 5%, cystitis in 4%, diarrhea in 3%, renal toxicity in 1%, and central nervous system toxicity in 1%. A Grade 2-4 regimen-related toxicity occurred in 109 patients (59%) and Grade 3-4 in eight patients (4%). Overall survival was 100% at Day 30, 96% at Day 90, and 89% at 1 year. Treatment-related mortality was 3.8%. In multivariate analyses that included prior chemotherapy, disease status, visceral metastases, prior chest radiation and age, CD34+ cell dose group was not an independent risk factor for Grade 2-4 mucositis, Grade 2-4 maximum toxicity, Grade ≥3 cumulative toxicity, 90 day survival or 1 year survival. Discussion: We conclude that CD34+ cell doses >20 X 106/kg do not affect transplant outcome in a negative or positive fashion.
KW - Autologous transplantation
KW - Breast cancer
KW - CD34 cells
KW - Peripheral blood stem cells
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=0033939059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033939059&partnerID=8YFLogxK
U2 - 10.1080/146532400539107
DO - 10.1080/146532400539107
M3 - Article
C2 - 12042047
AN - SCOPUS:0033939059
SN - 1465-3249
VL - 2
SP - 105
EP - 110
JO - Cytotherapy
JF - Cytotherapy
IS - 2
ER -